Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations
The company operates as a contract manufacturer and exporter of generic formulations, lacking significant brand power or proprietary R&D. While it possesses WHO-GMP certified facilities, the low net margins (3.6%) and average ROCE (13.1%) suggest a lack of durable pricing power or high switching costs.
Earnings are primarily reinvested into capacity expansion, such as the new Beta-lactam facility and solar energy projects. While revenue growth is steady, the company maintains a conservative dividend policy (zero payouts) and utilizes moderate debt to fund construction.
The company's aggressive capacity expansion into Beta-lactam facilities proved to be a capital trap as generic pricing compressed further, leaving the firm with idle assets and a fixed cost base it couldn't support. The razor-thin 3.6% net margins evaporated under the weight of increased depreciation and interest costs, while the poor cash conversion cycle (0.52) led to a liquidity crunch. Management's history of administrative lapses and frequent auditor turnover eventually culminated in a material accounting restatement that destroyed market confidence, proving that the business lacked the scale or brand power to survive a cyclical downturn in the export market.
RichFakir rates Medico Remedies Ltd's business quality as decent — 55/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Medico Remedies Ltd is trading about 6% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Medico Remedies Ltd is: Watch — wait for price. A decent business, but at a fair price against our estimate of fair value — one to keep on the watchlist for a better entry.
RichFakir's educational estimate of Medico Remedies Ltd's fair value is about ₹20 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →